Next-generation ADC therapies for hard-to-treat cancers.
Immunomedics was a clinical-stage biopharmaceutical company pioneering next-generation antibody-drug conjugate (ADC) technology for the targeted treatment of cancer, including triple-negative breast cancer and other solid tumors. Its lead drug, Trodelvy (sacituzumab govitecan), received FDA approval before the company was acquired by Gilead Sciences for $21 billion in 2020.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2020
May 2020
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
